Expert Perspective: Advancing Ultra-Low Temperature Labels For Advanced Therapies And Vaccines

Before the pandemic, labels rated for –80°C or –196°C were a niche requirement. Today, labels that crack, peel, or fade under ultra-cold conditions can disrupt clinical supply chains, while vaccines that cannot be thawed during application introduce additional constraints.

In this Q&A, Julia Field, Senior Product Manager in the Clinical Trials Division at Thermo Fisher Scientific, draws on her background in biological sciences, clinical diagnostics, and bioproduction to explore the challenges of clinical labeling in extreme temperatures. She discusses where adhesive performance and material durability can become critical points of failure, and how qualification studies help inform material selection for demanding storage and handling environments. The conversation also explores evolving customer expectations as standards for ultra-cold labeling have risen.

Read the full Q&A to learn how a clinical labeling specialist approaches these conditions, evaluates material performance, and considers the challenges involved in ensuring labels remain fit for purpose throughout clinical supply operations.